Short-Term Efficacy of Lebrikizumab Versus Dupilumab in Combination with Topical Corticosteroids in Adults with Moderate-to-Severe Atopic Dermatitis: Matching-Adjusted Indirect Comparison
Por:
Chovatiya, R, Armstrong, A, Kircik, L, Puig, L, Kirchhof, MG, Torres, T, Binamer, Y, Duarte, G, Akmaz, B, Dossenbach, M, Gallo, G, Yang, C, Seminario-Vidal, L, Ding, YX, Silverberg, JI
Publicada:
1 feb 2026
Ahead of Print:
1 dic 2025
Resumen:
IntroductionA matching-adjusted indirect comparison evaluated the short-term efficacy of lebrikizumab plus topical corticosteroids (TCS) versus dupilumab plus TCS in adults with moderate-to-severe atopic dermatitis (AD).MethodsIndividual patient data from the ADhere trial (lebrikizumab 250 mg every 2 weeks [Q2W] plus TCS) and aggregate data from the CHRONOS trial (dupilumab 300 mg Q2W plus TCS) were matched using the method of moments approach to adjust baseline differences. Matching was done at the study level (primary analysis) and at the study arm level (sensitivity analysis). Efficacy endpoints up to week 16 included the proportion of patients achieving an Investigator's Global Assessment of 0 or 1 (IGA 0/1); a >= 50%, >= 75%, and >= 90% improvement from baseline in the Eczema Area and Severity Index (EASI 50/75/90); a >= 4-point improvement from baseline in the Pruritus Numerical Rating Scale score (PNRS >= 4); and a >= 4-point improvement from baseline in the Dermatology Life Quality Index score (DLQI >= 4). Placebo-adjusted efficacy outcomes were compared using odds ratios (ORs), risk ratios (RRs), and risk differences (RDs) with 95% confidence intervals (CIs).ResultsAt week 16, lebrikizumab plus TCS had comparable odds to dupilumab plus TCS of achieving EASI 75 (OR 1.14, 95% CI 0.42-3.09), IGA 0/1 (OR 1.39, 95% CI 0.42-4.59), PNRS >= 4 (OR 0.48, 95% CI 0.17-1.37), and DLQI >= 4 (OR 0.89, 95% CI 0.29-2.69). At earlier timepoints, lebrikizumab plus TCS had comparable odds to dupilumab plus TCS of achieving PNRS >= 4 at week 2 (OR 2.04, 95% CI 0.24-17.05) and week 4 (OR 3.59, 95% CI 0.90-14.36). RR and RD estimates were consistent with OR estimates of efficacy. Sensitivity analyses confirmed the findings of the primary analysis.ConclusionLebrikizumab plus TCS was comparable to dupilumab plus TCS across all efficacy endpoints at week 16.
Filiaciones:
Chovatiya, R:
Rosalind Franklin Univ Med & Sci, Chicago Med Sch, N Chicago, IL 60064 USA
Ctr Med Dermatol Immunol Res, Chicago, IL 60657 USA
Armstrong, A:
Univ Southern Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA USA
Kircik, L:
Icahn Sch Med Mt Sinai, New York, NY USA
Indiana Univ, Sch Med, Indianapolis, IN USA
Puig, L:
Hosp Santa Creu & Sant Pau, Dept Dermatol, Barcelona, Spain
Kirchhof, MG:
Univ Ottawa, Fac Med, Div Dermatol, Ottawa, ON, Canada
Ottawa Hosp, Ottawa, ON, Canada
Torres, T:
Univ Porto, Ctr Hosp Univ Santo Antonio, Porto, Portugal
Binamer, Y:
King Faisal Specialist Hosp Res Ctr, Riyadh, Saudi Arabia
Alfaisal Univ, Riyadh, Saudi Arabia
Duarte, G:
Inst Bahiano Imunoterapia IBIS, Salvador, Brazil
Akmaz, B:
Almirall SA, Barcelona, Spain
Dossenbach, M:
Eli Lilly & Co, Indianapolis, IN USA
Gallo, G:
Eli Lilly & Co, Indianapolis, IN USA
Yang, C:
Eli Lilly & Co, Indianapolis, IN USA
Seminario-Vidal, L:
Eli Lilly & Co, Indianapolis, IN USA
Ding, YX:
Eli Lilly & Co, Indianapolis, IN USA
Silverberg, JI:
George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC USA
Green Submitted, gold
|